Terns Pharmaceuticals Inc. (TERN) Climbs 29% Following Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
Tweet Send to a Friend
Terns Pharmaceuticals Inc. (NASDAQ: TERN) Climbs 29% Following Trial Results with TERN-601 Once-Daily Oral GLP-1R ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
